Powered by

Interim Report (Half Year) H2 2018: Resverlogix reports deterioration in EPS Corporate Wire Date: 31 December 2018 22:58 EST

Jan 01, 2019 - News Bites Canadian Markets

CANADIAN RESULTS

Resverlogix (TSX:RVX) announced EPS of -49.0c for the half year-ended 31 October 2018, a deterioration from -24.0c in the previous corresponding period.

Major changes compared with previous corresponding period [Year-on-Year]:

Unfavourable Changes:

- EPS deterioration 104.2% from -24.0c to -49.0c

- Loss of $US88.7m

Interim (Half Year)

ACTIVITIES: Resverlogix Corp is a clinical stage cardiovascular company developing compounds involving ...